Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion.

Journal of endocrinological investigation - 1 Oct 2021

Colombo C, Foppiani A, Bisogno A, Gambazza S, Daccò V, Nazzari E, Leone A, Giana A, Mari A, Battezzati A

Abstract excerpt

PURPOSE: The question whether the new cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs aimed at restoring CFTR protein function might improve glucose metabolism is gaining attention, but data on the effect of lumacaftor/ivacaftor treatment (LUMA/IVA) on glucose tolerance are limited. We evaluated the variation in glucose metabolism and insulin secretion in CF patients homozygous for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Aminopyridines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzodioxoles

Share to Blood Glucose

Share to Chloride Channel Agonists

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Insulin Secretion

Share to Quinolones

Source

Open in PubMed Open full text

Identifiers

PMID: 33586024
DOI: 10.1007/s40618-021-01525-4
PMCID: PMC8421269

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion.PMID 33586024Read ↗

Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.Semantic proximity Read ↗

Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor.Semantic proximity Read ↗

Changes in glucose tolerance in people with cystic fibrosis after initiation of first-generation CFTR modulator treatment.Semantic proximity Read ↗

Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study.Semantic proximity Read ↗

Improved glucose tolerance after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis.Semantic proximity Read ↗

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR.Semantic proximity Read ↗

Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: Decline in HbA1c after elexacaftor/tezacaftor/ivacaftor treatment.Semantic proximity Read ↗

Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.Semantic proximity Read ↗

Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes.Semantic proximity Read ↗

CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation.Semantic proximity Read ↗

One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational StudySemantic proximity Read ↗

Improvements in Glucose Regulation in Children and Young People with Cystic Fibrosis-Related Diabetes following Initiation of Elexacaftor/Tezacaftor/Ivacaftor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.